Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

Sara Tomei, Ena Wang, Lucia Gemma Delogu, Francesco M. Marincola, Davide Bedognetti

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: Melanoma is an aggressive disease characterized by a complex etiology. The discovery of key driving mutations (primarily BRAF mutations) led to the development of specific molecular inhibitors providing clinical benefit. Areas covered: Although BRAF-specific drugs have perhaps yielded the best results in melanoma-targeted therapy, there still remain several limitations, mostly due to the emergence of resistance and the lack of efficacy in patients without BRAF mutation. Novel drugs are currently being tested in clinical trials and showed encouraging results. Such drugs can specifically target molecular pathways aberrantly activated or repressed during melanoma development (targeted therapy) or act in a way to enhance the host immune system to fight cancer (immunotherapy). Here we provide a detailed overview of the current clinical strategies, which lay beyond BRAF-targeted therapy, spanning from molecular-targeted therapy to immunotherapy and to combination therapy. Expert opinion: Major advances in our understanding of the mechanisms behind melanoma development have led to the implementation of novel therapeutic drugs. Unfortunately, tools allowing prediction of responsiveness to a given treatment are not available yet. The increasing availability of high-throughput technologies will allow the elucidation of molecular mechanisms underlying responsiveness to cancer therapy and unveil an increased number of potential therapeutic targets.

Original languageEnglish
Pages (from-to)663-686
Number of pages24
JournalExpert Opinion on Biological Therapy
Volume14
Issue number5
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Immunotherapy
Melanoma
Pharmaceutical Preparations
Immune system
Mutation
Therapeutics
Molecular Targeted Therapy
Throughput
Availability
Expert Testimony
Immune System
Neoplasms
Clinical Trials
Technology

Keywords

  • Adoptive T-cell transfer
  • Combination therapy
  • Immunotherapy
  • Melanoma
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. / Tomei, Sara; Wang, Ena; Delogu, Lucia Gemma; Marincola, Francesco M.; Bedognetti, Davide.

In: Expert Opinion on Biological Therapy, Vol. 14, No. 5, 2014, p. 663-686.

Research output: Contribution to journalReview article

@article{aaf93b7276e04ccc9234bb708d27424c,
title = "Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma",
abstract = "Introduction: Melanoma is an aggressive disease characterized by a complex etiology. The discovery of key driving mutations (primarily BRAF mutations) led to the development of specific molecular inhibitors providing clinical benefit. Areas covered: Although BRAF-specific drugs have perhaps yielded the best results in melanoma-targeted therapy, there still remain several limitations, mostly due to the emergence of resistance and the lack of efficacy in patients without BRAF mutation. Novel drugs are currently being tested in clinical trials and showed encouraging results. Such drugs can specifically target molecular pathways aberrantly activated or repressed during melanoma development (targeted therapy) or act in a way to enhance the host immune system to fight cancer (immunotherapy). Here we provide a detailed overview of the current clinical strategies, which lay beyond BRAF-targeted therapy, spanning from molecular-targeted therapy to immunotherapy and to combination therapy. Expert opinion: Major advances in our understanding of the mechanisms behind melanoma development have led to the implementation of novel therapeutic drugs. Unfortunately, tools allowing prediction of responsiveness to a given treatment are not available yet. The increasing availability of high-throughput technologies will allow the elucidation of molecular mechanisms underlying responsiveness to cancer therapy and unveil an increased number of potential therapeutic targets.",
keywords = "Adoptive T-cell transfer, Combination therapy, Immunotherapy, Melanoma, Targeted therapy",
author = "Sara Tomei and Ena Wang and Delogu, {Lucia Gemma} and Marincola, {Francesco M.} and Davide Bedognetti",
year = "2014",
doi = "10.1517/14712598.2014.890586",
language = "English",
volume = "14",
pages = "663--686",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

AU - Tomei, Sara

AU - Wang, Ena

AU - Delogu, Lucia Gemma

AU - Marincola, Francesco M.

AU - Bedognetti, Davide

PY - 2014

Y1 - 2014

N2 - Introduction: Melanoma is an aggressive disease characterized by a complex etiology. The discovery of key driving mutations (primarily BRAF mutations) led to the development of specific molecular inhibitors providing clinical benefit. Areas covered: Although BRAF-specific drugs have perhaps yielded the best results in melanoma-targeted therapy, there still remain several limitations, mostly due to the emergence of resistance and the lack of efficacy in patients without BRAF mutation. Novel drugs are currently being tested in clinical trials and showed encouraging results. Such drugs can specifically target molecular pathways aberrantly activated or repressed during melanoma development (targeted therapy) or act in a way to enhance the host immune system to fight cancer (immunotherapy). Here we provide a detailed overview of the current clinical strategies, which lay beyond BRAF-targeted therapy, spanning from molecular-targeted therapy to immunotherapy and to combination therapy. Expert opinion: Major advances in our understanding of the mechanisms behind melanoma development have led to the implementation of novel therapeutic drugs. Unfortunately, tools allowing prediction of responsiveness to a given treatment are not available yet. The increasing availability of high-throughput technologies will allow the elucidation of molecular mechanisms underlying responsiveness to cancer therapy and unveil an increased number of potential therapeutic targets.

AB - Introduction: Melanoma is an aggressive disease characterized by a complex etiology. The discovery of key driving mutations (primarily BRAF mutations) led to the development of specific molecular inhibitors providing clinical benefit. Areas covered: Although BRAF-specific drugs have perhaps yielded the best results in melanoma-targeted therapy, there still remain several limitations, mostly due to the emergence of resistance and the lack of efficacy in patients without BRAF mutation. Novel drugs are currently being tested in clinical trials and showed encouraging results. Such drugs can specifically target molecular pathways aberrantly activated or repressed during melanoma development (targeted therapy) or act in a way to enhance the host immune system to fight cancer (immunotherapy). Here we provide a detailed overview of the current clinical strategies, which lay beyond BRAF-targeted therapy, spanning from molecular-targeted therapy to immunotherapy and to combination therapy. Expert opinion: Major advances in our understanding of the mechanisms behind melanoma development have led to the implementation of novel therapeutic drugs. Unfortunately, tools allowing prediction of responsiveness to a given treatment are not available yet. The increasing availability of high-throughput technologies will allow the elucidation of molecular mechanisms underlying responsiveness to cancer therapy and unveil an increased number of potential therapeutic targets.

KW - Adoptive T-cell transfer

KW - Combination therapy

KW - Immunotherapy

KW - Melanoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84898732158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898732158&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.890586

DO - 10.1517/14712598.2014.890586

M3 - Review article

VL - 14

SP - 663

EP - 686

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -